Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study (vol 401, pg 269, 2023)

被引：0
|
作者：
Verstovsek, S.
Gerds, A. T.
Vannucchi, A. M.
机构：
来源：
LANCET | 2023年 / 401卷 / 10386期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1426 / 1426
页数：1
相关论文
共 50 条
  • [31] Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study
    Raje, Noopur
    Terpos, Evangelos
    Willenbacher, Wolfgang
    Shimizu, Kazuyuki
    Garcia-Sanz, Ramon
    Durie, Brian
    Legiec, Wojciech
    Krejci, Marta
    Laribi, Kamel
    Zhu, Li
    Cheng, Paul
    Warner, Douglas
    Roodman, G. David
    LANCET ONCOLOGY, 2018, 19 (03): : 370 - 381
  • [32] Transform-1: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, International Phase 3 Study of Navitoclax in Combination with Ruxolitinib Versus Ruxolitinib Plus Placebo in Patients with Untreated Myelofibrosis
    Pemmaraju, Naveen
    Mead, Adam J.
    Somervaille, Tim C. P.
    McCloskey, James K.
    Palandri, Francesca
    Koschmieder, Steffen
    Lavie, David
    Leber, Brian
    Yeh, Su-Peng
    Gomez-Casares, Maria Teresa
    Ammatuna, Emanuele
    Shin, Ho-Jin
    Kirito, Keita
    Jourdan, Eric
    Devos, Timothy
    Chuah, Hun S.
    Radinoff, Atanas
    Bogdanovic, Andrija
    Moskal, Rastislav
    Jiang, Qi
    Chopra, Avijeet S.
    Papadopoulos, Elektra
    Potluri, Jalaja
    Passamonti, Francesco
    BLOOD, 2023, 142
  • [33] Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study
    Dasari, Arvind
    Lonardi, Sara
    Garcia-Carbonero, Rocio
    Elez, Elena
    Yoshino, Takayuki
    Sobrero, Alberto
    Yao, James
    Garcia-Alfonso, Pilar
    Kocsis, Judit
    Gracian, Antonio Cubillo
    Sartore-Bianchi, Andrea
    Satoh, Taroh
    Randrian, Violaine
    Tomasek, Jiri
    Chong, Geoff
    Paulson, Andrew Scott
    Masuishi, Toshiki
    Jones, Jeremy
    Csoszi, Tibor
    Cremolini, Chiara
    Ghiringhelli, Francois
    Shergill, Ardaman
    Hochster, Howard S.
    Krauss, John
    Bassam, Ali
    Ducreux, Michel
    Elme, Anneli
    Faugeras, Laurence
    Kasper, Stefan
    Van Cutsem, Eric
    Arnold, Dirk
    Nanda, Shivani
    Yang, Zhao
    Schelman, William R.
    Kania, Marek
    Tabernero, Josep
    Eng, Cathy
    LANCET, 2023, 402 (10395): : 41 - 53
  • [34] Secukinumab in patients with psoriatic arthritis and axial manifestations: results from the double-blind, randomised, phase 3 MAXIMISE trial
    Baraliakos, Xenofon
    Gossec, Laure
    Pournara, Effie
    Jeka, Slawomir
    Mera-Varela, Antonio
    D'Angelo, Salvatore
    Schulz, Barbara
    Rissler, Michael
    Nagar, Kriti
    Perella, Chiara
    Coates, Laura C.
    ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 (05) : 582 - 590
  • [35] Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial (vol 396, pg 759, 2020)
    Olivotto, I
    Oreziak, A.
    Barriales-Villa, R.
    LANCET, 2020, 396 (10253): : 758 - 758
  • [36] BARICITINIB IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE): RESULTS FROM A PHASE 2, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY
    Wallace, D. J.
    Furie, R. A.
    Tanaka, Y.
    Kalunian, K. C.
    Mosca, M.
    Petri, M. A.
    Dorner, T.
    Cardiel, M. H.
    Bruce, I. N.
    Gomez, E.
    Carmack, T.
    Janes, J. M.
    Linnik, M. D.
    Silk, M.
    Hoffman, R.
    ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 59 - 59
  • [37] Reducing the impact of migraine on functioning: Results from the STRIVE trial, a phase 3, randomised, double-blind, placebo-controlled study of erenumab in patients with episodic migraine
    Buse, Dawn C.
    Lipton, Richard B.
    Mikol, Daniel D.
    Thach, Andrew V.
    Desai, Pooja
    Picard, Hernan
    Kubo, Yumi
    Hareendran, Asha
    Kawata, Ariane K.
    JOURNAL OF HEADACHE AND PAIN, 2017, 18
  • [38] Efficacy and safety of tocilizumab in patients with refractory Takayasu arteritis: results from a randomised, double-blind, placebo-controlled, phase 3 trial in Japan (the TAKT study)
    Nakaoka, Yoshikazu
    Isobe, Mitsuaki
    Takei, Syuji
    Tanaka, Yoshiya
    Ishii, Tomonori
    Yokota, Shumpei
    Nomura, Akira
    Yoshida, Seitaro
    Nishimoto, Norihiro
    ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 (03) : 348 - 354
  • [39] Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials (vol 3, pg 355, 2015)
    Castro, M.
    Zangrilli, J.
    Wechsler, M. E.
    LANCET RESPIRATORY MEDICINE, 2016, 4 (10): : E50 - E50
  • [40] Safety and efficacy of daridorexant in patients with insomnia disorder: results from two multicentre, randomised, double-blind, placebo-controlled, phase 3 trials
    Mignot, Emmanuel
    Mayleben, David
    Fietze, Ingo
    Leger, Damien
    Zammit, Gary
    Bassetti, Claudio L. A.
    Pain, Scott
    Kinter, Dalma Seboek
    Roth, Thomas
    LANCET NEUROLOGY, 2022, 21 (02): : 125 - 139
12345